A clinical trial called PAT-MIND is testing whether psilocybin-assisted therapy can reduce the profound hopelessness and loss of meaning — called demoralization — that many people with advanced cancer experience. The prediction is that the trial will report encouraging early results by late November 2026. This matters because cancer patients with terminal diagnoses represent one of the most ethically compelling cases for psychedelic therapy, and positive results here could open a faster path to availability.
Palliative populations tolerate open-label expectancy better and the trial is actively enrolling; the wedge indication is designed to be unblinding-resistant.
Join our community — a free weekly Zoom circle with a master facilitator. Come sit with us first; the rest reveals itself.
Join the Free Weekly Circle →